XMEX: FHIPO14
Morningstar‘s Stock Analysis FHIPO14
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile FHIPO14
Banco Invex SA Institucion De Banca Multiple-Invex Grupo Financiero is a Mexican financial institution which delivers specialized solutions. The company's business divisions are Private Banking, Business Banking, Cards, Trust, Infrastructure, and Leasing. The services provided by the company includes provision of banking and credit financial services, transactional and fiduciary services, granting of finance to corporate clients, large and medium-sized businesses through commercial loans, working capital credit lines, and other. It also offers various products such as the issuance of letters of credit, transactions with derivatives, financial counseling, and financial factoring operation.
Mexico City, DF, 11000, MEX
FAQs for Banco Invex SA Institucion De Banca Multiple-Invex Grupo Financiero Certifi Stock
No. FHIPO14 does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
FHIPO14’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare FHIPO14’s historical performance against its industry peers and the overall market.